Cancer/testis antigens for therapeutic use

Journal of B.U.ON.

Volumn 14, Issue SUPPL.1, 2009, Pages

  Mathieu, Morgan G ^a   Miles, A K ^a   Li, G ^b   McArdle, S E B ^a   Rees, R C ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b Centralabs   (United Kingdom)

Author keywords

Cancer vaccine; Cancer testis antigen; HAGE; Helicases; Immunotherapy; T21

Indexed keywords

BCR ABL PROTEIN; CANCER TESTIS ANTIGEN; CANCER TESTIS ANTIGEN HAGE; CANCER TESTIS ANTIGEN T21; HLA A2 ANTIGEN; HLA DR1 ANTIGEN; HLA DR4 ANTIGEN; MESSENGER RNA; RNA HELICASE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; BINDING AFFINITY; CANCER TISSUE; CELL PROLIFERATION; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MOTIF; RNA METABOLISM; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR LOCALIZATION;

ANTIGENS, NEOPLASM; CHROMOSOME MAPPING; FEMALE; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MALE; TESTICULAR NEOPLASMS; TESTIS; UTERINE CERVICAL NEOPLASMS;

EID: 70350050237     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
2. Jäger E, Nagata Y, Gnjatic S et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000; 97: 4760-4765. (Pubitemid 30238631)
3. Zeng G. MHC class II-restricted tumor antigens recognised by CD4+ T cells: new strategies for cancer vaccine design. J Immunother 2001; 24: 195-204. (Pubitemid 32479709)
4. Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-729. (Pubitemid 129505074)
5. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647. (Pubitemid 21917508)
6. Scanlan MJ, Simpson AJG, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immunol 2004; 4: 1-15.
7. Valmori D, Souleimanian NE, Hesdorffer CS et al. Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses. Clin Immunol 2005; 117: 24-30. (Pubitemid 41725466)
8. Zhao Y, Zheng Z, Robbins PF et al. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 2005; 174: 4415-4423. (Pubitemid 40396025)
9. Miles AK, Rogers A, Li G et al. Identification of a novel prostate cancer-associated tumor antigen. Prostate 2007; 67: 274-287. (Pubitemid 46255786)
10. Martelange V, De Smet C, De Plaen E et al. Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res 2000; 60: 3848-3855. (Pubitemid 32204577)
11. Eichmüller S, Usener D, Dummer R et al. Serological detection of cutaneous T cell lymphoma-associated antigens. Proc Natl Acad Sci U S A 2001; 98: 629-634. (Pubitemid 32105094)
12. Zendman AJ, Cornelissen IM, Weidle UH et al. CTp11, a novel member of the family of human cancer/testis antigens. Cancer Res 1999; 59: 6223-6229.
13. Westbrook VA, Diekman AB, Naaby-Hansen S et al. Differential nuclear localization of the cancer/testis-associated protein, SPAN-X/CTp11, in transfected cells and in 50% of human spermatozoa. Biol Reprod 2001; 64: 345-358. (Pubitemid 32044645)
14. Boeckmann B, Bairoch A, Apweiler R et al. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res 2003; 31: 365-370. (Pubitemid 36157284)
15. Caruthers JM, McKay DB. Helicase structure and mechanism. Curr Opin Struct Biol 2002; 12: 123-133.
16. Rocak S, Linder P. DEAD-box proteins: the driving forces behind RNA metabolism. Nat Rev Mol Cell Biol 2004; 5: 232-241. (Pubitemid 38325804)
17. Silverman E, Edwalds-Gilbert G, Lin RJ. DExD/H-box proteins and their partners: helping RNA helicases unwind. Gene 2003; 312: 1-16. (Pubitemid 37338108)
18. Cordin O, Banroques J, Tanner NK et al. The DEAD-box protein family of RNA helicases. Gene 2006; 367: 17-37. (Pubitemid 43286737)
19. Amler LC, Schurmann J, Schwab M. The DDX1 gene maps within 400 kbp 5′ to MYCN and is frequently coamplified in human neuroblastoma. Genes Chromosomes Cancer 1996; 15: 134-137. (Pubitemid 126426329)
20. Godbout R, Packer M, Bie W. Overexpression of a DEAD box protein (DDX1) in neuroblastoma and retinoblastoma cell lines. J Biol Chem 1998; 273: 21161-21168. (Pubitemid 28385405)
21. Eberle J, Fecker LF, Bittner JU et al. Decreased proliferation of human melanoma cell lines caused by antisense RNA against translation factor eIF-4A1. Br J Cancer 2002; 86: 1957-1962. (Pubitemid 34888635)
22. Wilson BJ, Bates GJ, Nicol SM et al. The p68 and p72 DEAD box RNA helicases interact with HDAC1 and repress transcription in a promoter-specific manner. BMC Mol Biol 2004; 5: 11.
23. Akao Y, Marukawa O, Marukawa H et al. The rck/p54 candidate proto-oncogene product is a 54-kilodalton D-E-A-D box protein differentially expressed in human and mouse tissues. Cancer Res 1995; 55: 3444-3449.
24. Nagel H, Laskawi R, Eiffert H et al. Analysis of the tumour suppressor genes, FHIT and WT-1, and the tumour rejection genes, BAGE, GAGE-1/2, HAGE, MAGE-1, and MAGE-3, in benign and malignant neoplasms of the salivary glands. MoI Pathol 2003; 56: 226-231. (Pubitemid 36981156)
25. Adams SP, Sahota SS, Mijovic A et al. Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia 2002; 16: 2238-2242. (Pubitemid 35331839)
26. Condomines M, Hose D, Raynaud P. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol 2007; 178: 3307-3315. (Pubitemid 46333216)
27. Sasaki H, Moriyama S, Mizuno K et al. SAGE mRNA expression in advanced-stage lung cancers. Eur J Surg Oncol 2003; 29: 900-903. (Pubitemid 37493291)
28. Mathieu MG, Knights AJ, Pawelec G et al. HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. Cancer Immunol Immunother 2007; 56: 1885-1895. (Pubitemid 47512610)
29. Roman-Gomez J, Jimenez-Velasco A, Agirre X et al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. Haematologica 2007; 92: 153-162. (Pubitemid 46852415)
30. Riley CL, Mathieu MG, Clark RE et al. Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable? Cancer Immunol Immunother 2009; 58: 1489-1499.